MAPKAP1

Across TCGA pan-cancer cohorts, MAPKAP1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPKAP1 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAPKAP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAPKAP1 expression acts as an unfavorable survival marker.

LUAD, STAD, and LUSC are the cancer types where MAPKAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.278	0.675	.006	9	view →
STAD	OS	Median	II,III,IV	0.172	0.662	.001	6	view →
LUSC	DFS	Median	All	0.180	0.796	.001	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPKAP1–LUAD (OS)

Open the LUAD breakdown →